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Associations between change inblood pressure and
functional outcome, early events and death: results
from the Efficacy of Nitric Oxide in Stroke trial
Else C. Sandseta, Jason P. Appletonc, Eivind Bergeb, Hanne Christensend, John Gommanse,
Kailash Krishnanc, George Ntaiosf, Stephen Phillipsg, Stuart Pocockh, Nikola Spriggc,
Lisa J. Woodhousec, Philip M. Bathc, on behalf of ENOS trial investigators
Objectives: High blood pressure (BP) is associated with a
poor outcome after acute stroke. Early reduction in BP
may be associated with fewer early adverse events and
deaths, and improved functional outcome.
Methods: Analyses used data from the Efficacy of Nitric
Oxide in Stroke trial, a multicentre randomized single-
masked and outcome-masked trial of glyceryl trinitrate vs.
no glyceryl trinitrate in 4011 patients recruited within 48h
of an ischaemic or haemorrhagic stroke and with raised
SBP (140–220mmHg). Change in SBP from baseline to day
1 was categorized as: more than 15% decrease, 15–5%
decrease, 5% decrease to 5% increase (no change –
reference) and more than 5% increase. The primary
outcome was functional outcome (modified Rankin scale)
score at 90 days.
Results: Across all patients, both moderate (5–15%) and
large (>15%) decreases in SBP were associated with
beneficial shifts in the modified Rankin scale relative to
patients with no change in BP: adjusted common odds
ratio (OR) 0.81 [95% confidence interval (CI) 0.70–0.90]
and OR 0.84 (95% CI 0.71–1.00), respectively. A
moderate decrease in SBP was also associated with a lower
risk of early adverse events, adjusted OR 0.69 (95% CI
0.52–0.90).
Conclusion: Modest decreases in SBP in acute stroke
appear to be associated with fewer early events and better
long-term functional outcome.
Keywords: acute stroke, blood pressure, glyceryl trinitrate
Abbreviations: BP, blood pressure; CI, confidence
interval; ENOS, Efficacy of Nitric Oxide in Stroke; GTN,
glyceryl trinitrate; mRS, modified Rankin scale; OR, odds
ratio
INTRODUCTION
H
igh blood pressure (BP) in acute stroke is common
[1,2], and has been associated with poor short and
long-term outcome in epidemiological studies [1].
Yet, randomized clinical trials have failed to show a bene-
ficial effect of lowering BP in the acute phase [3–5].
One concern regarding early BP lowering, especially in
ischaemic stroke, is the risk of cerebral hypoperfusion and
progression of infarction. Previous studies have reported
associations between large fluctuations of BP in acute
stroke and early adverse events such as stroke progression
and neurological deterioration [6–8].
The Efficacy of Nitric Oxide in Stroke (ENOS) trial found
no overall beneficial effects of BP lowering using a trans-
dermal glyceryl trinitrate (GTN) patch in acute stroke [5]. In
the prespecified subgroup of patients treated within 6 h of
stroke onset, treatment with GTN appeared to reduce the
risk of poor outcome, perhaps by increasing collateral
circulation [9,10]. Associations between change in SBP
within the first day of randomization, and early events at
7 days and, death and functional outcome at 3 months, are
assessed in this secondary analysis of ENOS which involves
patients recruited into the trial.
METHODS
The ENOS study design, statistical analysis plan and partic-
ipants have been described in detail elsewhere [5,11,12].
Briefly, 4011 patients presenting within 48h of acute ischae-
mic or haemorrhagic strokewere randomized in single blind
design to treatment with a GTNpatch or to noGTNpatch for
7 days; thosewho used BP lowering treatments at the time of
stroke were also randomized to continue or stop this
treatment in a partial factorial design. At baseline, BP was
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measured three times – at least one of the three systolic
measurements had to be in the range 140–220mmHg before
enrolment and the mean of the three was used in analyses.
During the treatment period, BPwasmeasured twice, at least
1–2h after placement of the daily patch (GTN or no GTN).
For all measurements, BP was measured by trained person-
nel using the nonparetic arm, with the patient supine or
sitting; an automatedand validatedBPmonitorwasprovided
to each hospital site for use in the trial (OMRON Healthcare
Company, Kyoto, Japan) [5].
Effect parameters
The primary effect parameter was functional outcome at 90
days, measured centrally by telephone, using the 7-level
modified Rankin scale (mRS scores range from 0 to 6, with a
score of 0 indicating no symptoms, 1 indicating some
symptoms, 2–5 indicating increasing levels of disability
and dependency and 6 indicating death). Secondary effect
parameters were the end-point of early neurological events,
this combining early recurrent stroke or neurological dete-
rioration by 7 days; and death from any cause at 90 days.
Early recurrent stroke was classified as haemorrhagic,
ischaemic or unknown type. Neurological deterioration
was defined as a reduction in Scandinavian Stroke Scale
(SSS) score of at least five points, or a decrease in con-
sciousness level of at least three points [5].
Statistical analysis
All data were collected prospectively, and analyses used the
intention-to-treat population of ENOS [12]. The greatest
drop in BP occurred between admission (day 0) and day
1; the proportional difference between the measurements
was used as a measure for change in SBP: DSBP¼ (SBP day
0 SBP day 1)/SBP day 0. Patients were categorized into
groups according to the proportional change in SBP, iden-
tifying patients with a large decrease (>15%), moderate
decrease (15–5%), no change (5% decrease to 5% increase,
reference group) or increase (>5%). Baseline differences
among the four groups were compared using Chi-squared
test for categorical variables and one-way analysis of vari-
ance with P values for linear trend for continuous variables.
Functional outcome at 90 days was analysed using
ordinal logistic regression and is reported as adjusted
common odds ratios (acORs) with 95% confidence intervals
(CIs). The end-points of combined early recurrent stroke
and neurological deterioration, and all cause death at 90
days, were analysed using binary logistic regression. Anal-
yses was adjusted for: age, sex, premorbid mRS score,
history of previous stroke, history of diabetes mellitus,
stroke severity (SSS), stroke syndrome (Oxfordshire Com-
munity Stroke Project classification), stroke type (ischae-
mic, haemorrhagic, unknown type, not stroke), SBP at
baseline, treatment with alteplase, feeding status and time
to randomization. In the analyses including all patients,
adjustment also included GTN vs. no GTN. In addition, to
control for the effect of trial treatment, analyses were
performed separately for patients in the GTN and no
GTN groups, including tests for heterogeneity. As a sensi-
tivity analysis we included the mean SBP [(day 0þday 1)/2]
in the models. All analyses were carried out in the sub-
groups according to baseline BP, time to randomization and
stroke subtype. Analyses were performed using SPSS
version 21 (Chicago, Illinois, USA) and 2P at least 0.05 is
considered significant [12].
RESULTS
BP measurements were available in 3851 patients (97%).
Baseline characteristics are presented in Table 1. A reduc-
tion in SBP was observed in 2495 patients (65%) and an
increase in 1356 patients (35%). Gradients were apparent
across the four groups of patients with those who exhibited
amore than 15% decrease in BP having a higher baseline BP
and less severe strokes than those whose BP increased over
the first day (Table 1). A significantly higher proportion of
patients showing a more than 15% decrease in BP were
randomized to treatment with GTN (P< 0.0001). There
were more haemorrhagic strokes among patients with no
change in BP, and more patients with total anterior stroke
syndromes in patients with an increase in BP.
The association between relative change in SBP and
functional outcome is shown in Fig. 1. A moderate reduc-
tion in SBP of 5–15% was associated with a beneficial shift
in the mRS (OR 0.81, 95% CI 0.70–0.93). Similar results were
seen in patients with a more than 15% decrease in BP (OR
0.84, 95% CI 0.71–1.00). There was no association between
increase in BP and functional outcome. When assessed by
treatment group, the results did not differ between the GTN
and no-GTN groups (P for interaction¼ 0.59). Similar
results were seen when analysing by absolute rather than
relative change (data not shown).
Table 2 shows associations between change in BP and
early clinical and neurological events 7 days and death at 90
days. Amoderate reduction in BPwas associatedwith fewer
early clinical and neurological events (OR 0.69, 5% CI 0.52–
0.90), whereas an increase in BP was significantly associ-
ated with death at 90 days (OR 1.51, 95% CI 1.14–2.00;
P¼ 0.005). Including mean SBP (SBP day 0 þ SBP day 1)/2
did not alter the results.
Associations between change in BP and outcome
according to baseline SBP are shown in Table 3. In the
subgroup of patients with baseline BP 160–179mmHg, a
moderate relative reduction in BP of 5–15% was associated
with fewer early neurological events (acOR 0.51, 95% CI
0.32–0.81). In the same subgroup, a relative increase in BP
was associated with increased risk of death at 90 days (OR
1.99, 95% CI 1.19–3.32).
Table 4 shows associations between change in BP and
outcome according to time to randomization. In the group
treated very early (<6 h), there was a trend suggesting that a
larger decrease was associated with less early neurological
events at 7 days (OR 0.24, 95% CI 0.1–0.65). In patients
treated after 24 h, an increase in BP was associated with an
increased risk of death at 90 days (OR 1.61, 95% CI 1.10–
2.37). No difference was seen in the effect of change in BP
on either death or functional outcome at 90 days in the
other subgroups.
In ischaemic stroke a moderate BP decrease predicted
improved functional outcome at day 90 (OR 0.76, 95% CI
0.65–0.89, Table 5) and in intracerebral haemorrhage
increased BP was associated with increased risk of death
at day 90 (OR 2.27, CI 95% 1.11–4.62).
Change in blood pressure in acute stroke
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DISCUSSION
In this secondary on-treatment analysis of the ENOS trial,
a moderate relative reduction in SBP, independent of
treatment assignment, was associated with less early neu-
rological events and better functional outcome, whereas
an increase in BP was associated with an increased risk
of death.
High SBP at the time of hospital admission has been
associated with recurrent stroke, death and poor func-
tional outcome in several populations [1,7,13,14], whereas
results regarding change in BP in the acute phase of stroke
and outcome are conflicting. A secondary analysis of the
Scandinavian Candesartan Acute Stroke Trial (SCAST)
found an association between large decreases or increase
in BP and early adverse events [6]. However, there was no
association between change in BP and long-term func-
tional outcome, as seen in other trials [15]. The results
presented here show the opposite, that is, a moderate-to-
large relative reduction is associated with better outcome.
There may be several reasons for this. First, the patients
with a large decrease in BP had lower baseline SBP
as compared with the equivalent group in SCAST
(173.8 19.2 vs. 182.2 20.2mmHg). Second, the present
analyses used a relative measure of change in BP, which
may be more clinically relevant; in contrast, absolute
measures of change in BP were used in the SCAST sec-
ondary analysis. Finally, the overall achievedBP reduction
was greater in ENOS than in SCAST (7/4 vs. 3/1mmHg on
day 1) [3,5].
As reported in other populations, a relative increase in
SBP was associated with an increased risk of death at 90
days [15]. Patients in this group had lower BP and more
severe strokes at baseline, both known predictors of poor
outcome. It is unlikely that there is a causal relationship
between increases in BP and risk of death but an increase in
BP may be a marker of stroke severity, progression and
concurrent disease.
In patients treated very early, a large to moderate relative
reduction in SBP was associated with fewer early events.
This helps to explain the results of an earlier subgroup
analysis where transdermal GTN improved functional out-
come, cognition and mood, and reduced the risk of adverse
events and death in patients treated within 6 h of symptom
onset [9]. Another possible explanation could be the spon-
taneous fall in BP seen in patients with mild to moderate
stroke, who naturally have a better prognosis [16]. Also,
regression to the mean may in part have confounded the
results since the largest decline in SBP occurred in patients
with the highest BP at baseline.
TABLE 1. Baseline characteristics according to change in blood pressure groups
All
>15% Decrease
(large)
5–15% Decrease
(moderate)
5–5% Change
(reference)
>5% Increase
(increase) P
N 3851 593 1121 1412 725
Sex, female (%) 272 (45.9) 477 (42.6) 573 (40.6) 327 (45.1) 0.081
Age (years) 71.011.7 69.911.8 70.412.0 70.713.1 0.26
Premorbid mRS>0 (%) 164 (27.7) 286 (25.2) 344 (24.4) 205 (28.3) 0.17
Time to randomization (h) 26.713.2 25.313.0 26.312.8 25.612.3 0.18
Medical history (%)
Hypertension 387 (65.3) 728 (64.9) 908 (64.3) 483 (66.6) 0.77
Treated hypertension 333 (56.2) 586 (52.3) 745 (52.8) 395 (54.5) 0.40
Previous stroke 107 (18.0) 166 (14.8) 191 (13.5) 110 (15.2) 0.080
Previous TIA
Ischaemic heart disease 113 (19.1) 197 (17.6) 237 (16.8) 106 (14.6) 0.37
Peripheral artery disease
AF, current or previous 108 (18.2) 212 (18.9) 269 (19.1) 146 (20.1) 0.84
Diabetes mellitus 109 (18.4) 190 (16.9) 241 (17.1) 129 (17.8) 0.86
Nitrate use before stroke 26 (4.4) 42 (3.7) 32 (4.4) 48 (3.4) 0.60
Haemodynamics
SBP (mmHg) 173.819.2 169.718.8 166.018.3 160.317.5 <0.0001
DBP (mmHg) 92.713.3 90.512.3 88.913.3 86.213.0 <0.0001
Heart rate (bpm) 77.515.4 77.614.7 77.414.6 77.414.3 0.99
Qualifying event (%)
Ischaemic stroke 502 (84.7) 958 (85.5) 1155 (81.8) 602 (83.2) 0.030
Haemorrhagic 84 (14.2) 147 (13.1) 247 (17.5) 116 (16)
Other 0 0 0 1 (0.1)
Unknown 7 (1.2) 16 (1.4) 10 (0.7) 5 (0.7)
OCSP classification (%)
Total anterior 168 (28.3) 313 (27.9) 423 (30.0) 261 (36.0) 0.030
Partial anterior 188 (31.7) 347 (31.0) 447 (31.7) 219 (30.2)
Lacunar 212 (35.8) 417 (37.2) 494 (35.0) 219 (30.2)
Posterior 25 (4.2) 44 (3.9) 26 (3.6) 48 (3.4)
SSS score (/58) 38 (26–46) 37 (26–45) 36 (24–44) 33 (20–42) <0.0001
Thrombolytic treatment (%) 67 (11.3) 128 (11.4) 142 (10.8) 79 (10.9) 0.89
GTN treatment (%) 397 (66.9) 607 (54.1) 641 (45.4) 269 (37.1) <0.0001
Data are n (%), median (IQR) or mean (SD). P values are based on Chi-squared or Wilcoxon test. SSS scores range from 0 (coma with quadriplegia) to 58 (normal, no neurological
deficit). AF, atrial fibrillation; GTN, glyceryl trinitrate; IQR, interquartile range; mRS, modified Rankin scale; OCSP, Oxfordshire Community Stroke Project; SSS, Scandinavian Stroke Scale;
TIA, transient ischaemic attack.
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FIGURE 1 Associations between change in blood pressure and functional outcome at 90 days. acOR, adjusted common odds ratio; CI, confidence interval; GTN, glyceryl
trinitrate. Analysed using ordinal logistic regression. Adjusted for age, sex, premorbid modified Rankin scale, history of previous stroke, history of diabetes, severity, stroke
syndrome (total anterior circulation), stroke type (ischaemic, haemorrhagic, not stroke), SBP, alteplase, feeding status and time to randomization. In the analysis including
all patients, we also adjusted for trial treatment.
TABLE 2. Associations between change in blood pressure and risk of early adverse events (recurrent stroke, clinical and neurological
deterioration) at 7 days and death at 90 days
Recurrent stroke or clinical or neurological
deterioration at day 7
Adjusted analysis
Death at 90 days
Adjusted analysis
OR 95% CI P OR 95% CI P
All patients
>15% Decrease 0.96 0.70–1.31 0.026 1.01 0.72–1.42 0.005
5–15% Decrease 0.69 0.52–0.90 0.88 0.66–1.17
5–5% Increase 1 1
>5% Increase 1.04 0.79–1.37 1.51 1.14–2.00
GTN
>15% Decrease 1.07 0.71–1.61 0.112 1.15 0.73–1.81 0.192
5–15% Decrease 0.71 0.49–1.05 0.96 0.64–1.44
5–5% Increase 1 1
>5% Increase 1.19 0.78–1.83 1.53 0.98–2.40
No GTN
>15% Decrease 0.82 0.49–1.38 0.171 0.89 0.51–1.53 0.021
5–15% Decrease 0.65 0.44–0.96 0.83 0.57–1.24
5–5% Increase 1 1
>5% Increase 0.94 0.65–1.36 1.55 1.07–2.24
Analysed using binary multivariable logistic regression, adjusted for age, sex, premorbid mRs, history of previous stroke, history of diabetes, severity, stroke syndrome (total anterior
circulation), stroke type (ischaemic, haemorrhagic, not stroke), SBP, alteplase, feeding status and time to randomization. In the analysis including all patients, we also adjusted for trial
treatment. CI, confidence interval; GTN, glyceryl trinitrate; mRS, modified Rankin scale; OR, odds ratio.
Change in blood pressure in acute stroke
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The strength of this study is the large number of patients
with acute stroke and high BP with near complete data,
including serial standardized BP measurements with a
validated BP monitor. The major limitation of the study
is that the comparisons were nonrandomized. Further,
there is a risk of confounding when combining the GTN
and no GTN treatment groups, although the primary out-
come was neutral overall. Finally, there is the possibility of
chance findings, in part because of multiple testing. As a
result, these results should be interpreted with caution.
TABLE 3. Associations between change in blood pressure and early events, functional outcome and death at 90 days, by baseline blood
pressure
Recurrent stroke/Neurological
deterioration day 7a mRS day 90b Death at 90 daysa
OR 95% CI P acOR 95% CI P OR 95% CI P
SBP<159 – n¼1568
>15% Decrease 1.22 0.67–2.20 0.249 0.82 0.59–1.13 0.220 0.81 0.42–1.56 0.043
5–15% Decrease 0.65 0.40–1.08 0.73 0.58–0.92 0.009 0.76 0.46–1.25
5–5% Increase 1 1 1
>5% Increase 0.92 0.60–1.40 1.02 0.81–1.28 0.870 1.46 0.97–2.18
SBP 160–179 – n¼1447
>15% Decrease 0.61 0.34–1.10 0.008 0.80 0.60–1.07 0.128 0.89 0.48–1.67 0.039
5–15% Decrease 0.51 0.32–0.81 0.84 0.67–1.07 0.155 1.17 0.73–1.86
5–5% Increase 1 1 1
>5% Increase 1.13 0.70–1.82 1.24 0.92–1.66 0.156 1.99 1.19–3.32
SBP 180–199 – n¼744
>15% Decrease 1.01 0.56–1.82 0.95 0.97 0.66–1.42 0.874 1.52 0.75–3.07 0.433
5–15% Decrease 0.90 0.53–1.51 0.87 0.63–1.19 0.380 0.83 0.43–1.59
5–5% Increase 1 1 1
>5% Increase 1.11 0.72–1.71 0.82 0.52–1.2 0.416 1.04 0.45–2.42
SBP>200 – n¼252
>15% Decrease 3.12 0.94–10.4 0.126 0.98 0.50–1.90 0.944 0.83 0.27–2.54 0.347
5–15% Decrease 1.02 0.31–3.38 0.71 0.38–1.33 0.287 0.37 0.12–1.23
5–5% Increase 1 1
>5% Increase 2.27 0.60–8.66 0.83 0.35–1.97 0.667 0.81 0.21–3.10
acOR, adjusted common odds ratio; CI, confidence interval; mRS, modified Rankin scale; OR, odds ratio.
aAnalysed using binary multivariate logistic regression.
bAnalysed using ordinal logistic regression, adjusted for age, sex, premorbid mRS, history of previous stroke, history of diabetes, severity, stroke syndrome (total anterior circulation),
stroke type (ischaemic, haemorrhagic, not stroke), SBP, alteplase, feeding status and time to randomization.
TABLE 4. Associations between of change in blood pressure on early events, functional outcome and death at 90 days in subgroups
according to time to randomization
Recurrent stroke/Neurological
deterioration day 7a mRS day 90b Death at 90 daysa
OR 95% CI P acOR 95% CI P OR 95% CI P
6.0 h, n¼262
>15% Decrease 0.20 0.05–0.78 0.015 0.71 0.34–1.51 0.376 0.40 0.06–2.91 0.093
5–15% Decrease 0.24 0.10–0.65 0.80 0.45–1.40 0.431 0.35 0.08–1.55
5–5% Increase 1 1 1
>5% Increase 0.76 0.28–2.05 1.12 0.56–2.26 0.745 2.44 0.68–8.71
6.1–12.0 h, n¼424
>15% Decrease 0.43 0.15–1.18 0.324 0.82 0.48–1.41 0.476 1.33 0.53–3.36 0.625
5–15% Decrease 0.60 0.26–1.28 0.85 0.55–1.30 0.446 1.44 0.67–3.07
5–5% Increase 1 1 1
>5% Increase 0.67 0.28–1.63 0.63 0.37–1.06 0.082 1.76 0.73–4.22
12.1–24.0 h, n¼1032
>15% Decrease 1.32 0.76–2.32 0.132 0.71 0.50–1.01 0.055 1.14 0.72–2.63 0.348
5–15% Decrease 0.65 0.39–1.07 0.76 0.58–1.00 0.052 0.85 0.49–1.48
5–5% Increase 1 1 1
>5% Increase 0.95 0.57–1.59 1.01 0.74–1.38 0.943 1.38 0.79–2.40
>24.1 h, n¼1152
>15% Decrease 1.18 0.76–1.85 0.169 0.93 0.73–1.81 0.554 0.87 0.53–1.43 0.022
5–15% Decrease 0.87 0.50–1.29 0.83 0.68–1.00 0.055 0.87 0.59–1.30
5–5% Increase 1 1 1
>5% Increase 1.40 0.93–2.09 1.17 0.94–1.46 0.155 1.61 1.10–2.37
acOR, adjusted common odds ratio; CI, confidence interval; mRS, modified Rankin scale; OR, odds ratio.
aAnalysed using binary multivariate logistic regression.
bAnalysed using ordinal logistic regression, adjusted for age, sex, premorbid mRS, history of previous stroke, history of diabetes, severity, stroke syndrome (total anterior circulation),
stroke type (ischaemic, haemorrhagic, not stroke), SBP, alteplase and feeding status.
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In conclusion, a moderate-to-large decrease in SBP in
acute strokewas safe and associatedwith fewer early events
and better functional outcome at day 90.
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TABLE 5. Associations between change in blood pressure on early events, functional outcome and death at 90 days at end of follow-up in
subgroups according to stroke subtype
Recurrent stroke/Neurological
deterioration day 7a mRS day 90b Death at 90 daysa
OR 95% CI P acOR 95% CI P OR 95% CI P
Ischaemic stroke, n¼3218
>15% Decrease 0.95 0.67–1.35 0.068 0.80 0.66–0.97 0.020 0.87 0.59–1.29 0.017
5–15% Decrease 0.72 0.54–0.97 0.76 0.65–0.89 0.001 0.85 0.62–1.16
5–5% Increase 1 1 1
>5% Increase 1.01 1.00–1.03 1.08 0.90–1.29 0.424 1.43 1.05–1.95
Haemorrhagic stroke, n¼594
>15% Decrease 0.98 0.47–2.05 0.118 1.14 0.71–1.81 0.589 1.91 0.87–4.21 0.08
5–15% Decrease 0.44 0.21–0.89 1.07 0.74–1.56 0.708 1.11 0.53–2.31
5–5% Increase 1 1 1
>5% Increase 0.71 0.36–1.41 1.17 0.77–1.79 0.456 2.27 1.11–4.62
acOR, adjusted common odds ratio; CI, confidence interval; mRS, modified Rankin scale; OR, odds ratio.
aAnalysed using binary multivariate logistic regression.
bAnalysed using ordinal logistic regression, adjusted for age, sex, premorbid mRS, history of previous stroke, history of diabetes, severity, stroke syndrome (total anterior circulation), SBP,
alteplase, feeding status and time to randomization.
Change in blood pressure in acute stroke
Journal of Hypertension www.jhypertension.com 2109
